Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Intraoperative complications are similar whether staging of endometrial cancer is performed laparoscopically or by laparotomy, but laparoscopy has the advantage when it comes…
NEW YORK (Reuters Health) – Results of a study suggest that gonadotropin-releasing hormone (GnRH) agonist therapy does not help preserve ovarian function in young women undergoing modern chemotherapy…
NEW YORK (Reuters Health) – In a phase 2 study of maintenance therapy for metastatic colorectal cancer, adding enzastaurin to bevacizumab plus bolus and infusional 5-fluorouracil-leucovorin (LV5FU2) did…
NEW YORK (Reuters Health) – Cervical intraepithelial neoplasia grade 1 (CIN 1) found on biopsy provides no information on the risk of progression to CIN 3 beyond that…
NEW YORK (Reuters Health) – Cirrhosis and hepatitis are associated with the occurrence of hepatocellular carcinoma (HCC) in patients with diabetes, and hepatitis C is of particular importance,…
NEW YORK (Reuters Health) The first report of 10-year outcomes of hepatocellular carcinoma treated by percutaneous radio frequency ablation (RFA) indicates that about 1 in 4 patients survive…
NEW YORK (Reuters Health) – For women with breast cancer metastatic to bone, treatment with zoledronic acid to reduce skeletal complications does not prolong progression-free survival or overall…
NEW YORK (Reuters Health) – A large multicenter study confirms that placement of self-expanding metal stents in the colon in cases of malignant colorectal obstruction restores bowel transit…
NEW YORK (Reuters Health) – In recurrent ovarian cancer, combination docetaxel and carboplatin may provide an advantage in terms of progression-free survival (PFS) over sequential docetaxel-carboplatin, according to…
NEW YORK (Reuters Health) – Among patients with early stage non-small-cell lung cancer, treatment with gemcitabine and cisplatin before radical surgery is associated with better survival than is…
